Clinical trial statistics tell us where investigational drugs are tested. They do not tell us who owns the assets, who uses the evidence to obtain regulatory approvals or who captures the economic value when those drugs succeed.

If an experienced professional with rare expertise leaves Israel, the impact cannot be understood simply by adding another person to a brain-drain statistic. The more relevant question is how many people with comparable experience remain, how essential that expertise is and how easily it can be rebuilt.